Amgen Could Block Enbrel Biosimilars For Another Decade As Court Rules Stealth Patents Valid

Court rejects Sandoz's arguments that patents covering Enbrel's active ingredient and method of manufacture are invalid; decision comes three years after FDA approved Sandoz's biosimilar.

Tumor-necrosis
Court finds patents covering the TNF-IgG1 immunoglobulin fusion protein are valid.

Barring an appeals court reversal, Amgen Inc. may be able to keep biosimilars to its top-selling drug Enbrel (etancercept) off the market for another decade now that a district court has upheld the validity of patents covering the compound's active ingredient and method of manufacture.

Three years after Sandoz Inc. obtained FDA approval of its biosimilar Erelzi (etanercept-szzs), the US District Court for the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Biosimilars

More from Biosimilars & Generics